e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
COPD treatment: clinical trials, cohorts and inhaler device studies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Annual FEV1% variation before and after augmentation therapy in severe alpha-1-antitrypsin deficiency
G. Gonçalves (Coimbra, Portugal), S. Cabral (Coimbra, Portugal), A. Lopes (Coimbra, Portugal)
Source:
International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Session:
COPD treatment: clinical trials, cohorts and inhaler device studies
Session type:
Thematic Poster
Number:
4238
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Gonçalves (Coimbra, Portugal), S. Cabral (Coimbra, Portugal), A. Lopes (Coimbra, Portugal). Annual FEV1% variation before and after augmentation therapy in severe alpha-1-antitrypsin deficiency. 4238
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Mobile video directly observed therapy can be used to improve at-home inhaler technique in children with asthma
New inhaler devices: the good, the bad, and the ugly
Clinically appropriate testing of different valved holding chamber (VHC)-facemask combinations investigating simulated delivered mass to carina
Related content which might interest you:
Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients
Source: Virtual Congress 2021 – Treatments for airway diseases
Year: 2021
Long-term effect of a
1
-antitrypsin augmentation therapy on the decline of FEV
1
in deficient patients: an analysis of the AIR database
Source: ERJ Open Res, 7 (3) 00194-2021; 10.1183/23120541.00194-2021
Year: 2021
Intermediate and severe α
1
-antitrypsin deficiency: influence on plasma α
1
-antitrypsin, FEV
1
and risk of COPD. Three meta-anlyses
Source: Eur Respir J 2002; 20: Suppl. 38, 513s
Year: 2002
Prevalence of alpha1-antitrypsin deficiency and its influence on lung function decline in patients with severe asthma
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020
Lung function decline in relation to alpha-1-antitrypsin phenotypes in severe asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 479s
Year: 2003
One year follow-up of intrabronchial lung volume reduction in alpha-1-antitrypsin deficiency and severe emphysema
Source: Annual Congress 2011 - Treatment beyond inhalers: endoscopic lung volume reduction
Year: 2011
Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough
Source: Eur Respir J 2016; 47: 35-38
Year: 2016
Use of measurements of airway resistance in the determination of reversibility in patients with emphysema associated with alpha-1-antitrypsin (A1ATD) deficiency
Source: Eur Respir J 2001; 18: Suppl. 33, 205s
Year: 2001
Mortality
versus
FEV1, KCO and CT lung density measured at baseline in the UK alpha-1-antitrypsin deficiency assessment programme
Source: Eur Respir J 2001; 18: Suppl. 33, 91s
Year: 2001
Changes in FEV1 and SpO2 in patients with severe and very severe COPD
Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases
Year: 2021
Exacerbations and duration of smoking abstinence are associated with the annual decline in lung function in individuals with PiZZ alpha-1-antitrypsin deficiency
Source: International Congress 2017 – Current challenges in COPD evaluation
Year: 2017
Reducing the decline of FEV
1
after a 4-year therapy with montelukast in patients with bronchial asthma
Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD
Year: 2008
Association between weight loss and decline in FVC in patients with IPF
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Regular follow-up in severe asthma may reduce the rate of exacerbations and the FEV1 decline
Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases
Year: 2011
Treatment with corticosteroids and yearly decline of forced expiratory flow (FEV
1
) in patients with severe chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Respiratory structure and function
Year: 2008
Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012
Current and future therapy of lung emphysema caused by alpha-1-antitrypsin deficiency
Source: Annual Congress 2004 - Alpha-1-antitrypsin deficiency: Current knowledge and new frontiers
Year: 2004
ADAM33
SNPs are associated with excess FEV
1
decline in severe early onset COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 582s
Year: 2006
Decline of FEV
1
in different groups of severe refractory asthmatics
Source: Eur Respir J 2005; 26: Suppl. 49, 575s
Year: 2005
Exploring the relationship between alpha-1-antitrypsin deficiency and persistent airflow limitation in severe asthma.
Source: International Congress 2017 – Rare and common genetic variants of common and rare airway diseases
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept